Drug intelligence / Profile preview

NPC-1

Development stage: Unknown
Lead developer: Precise Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Oral

Overview

NPC-1 is a monoclonal antibody developed to target the mutated MUC5ac antigen, which is expressed in pancreatic cancer. It has demonstrated efficacy in animal models by inducing rapid tumor destruction through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). Safety and efficacy studies, including tissue cross-reactivity, biodistribution, and cytokine release assays, have been conducted, leading to the initiation of a Phase I clinical trial for pancreatic cancer.

Targets

MUC5AC (Mucin-5AC)

Beyond the preview

Go deeper on NPC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPC-1.

Explore the full profile